Verus Capital Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Verus Capital Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$46K	Buy	599 +224	+60%	+$19.8K	0.01%	529
2019 Q4	$36K	Buy	+375	New	+$32.4K	0.01%	701

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Bank of Nova Scotia Toronto, Ontario, Canada $66.2B AUM 46.3% 1-Year Est. Return

Verus Capital Partners's XBI Position: Q1 2020 in Review

Verus Capital Partners increased its State Street SPDR S&P Biotech ETF (XBI) stake by 60% in Q1 2020, buying an estimated $19.8K and bringing the position to 599 shares worth $46K. The position accounts for 0.01% of the portfolio, ranked #529.

Verus Capital Partners first reported a position in XBI in Q4 2019 and has held it in 2 quarters since. 458 funds tracked by Wall St. Rank hold XBI as of Q1 2020.

Verus Capital Partners held 599 shares of State Street SPDR S&P Biotech ETF worth $46K as of Q1 2020.
Verus Capital Partners bought 224 State Street SPDR S&P Biotech ETF shares in Q1 2020, an estimated $19.8K.
State Street SPDR S&P Biotech ETF made up 0.01% of Verus Capital Partners's portfolio in Q1 2020, its #529 holding.
Verus Capital Partners first reported a position in State Street SPDR S&P Biotech ETF in Q4 2019 and has held it in 2 quarters since.
458 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2020.

Based on Verus Capital Partners's 13F filing for Q1 2020, filed 26 May 2020.